KHẢO SÁT TÌNH HÌNH THEO DÕI NỒNG ĐỘ VANCOMYCIN TRONG ĐIỀU TRỊ NHIỄM KHUẨN TẠI MỘT BỆNH VIỆN Ở QUẬN 7

Abstract

Background: Therapeutic Drug Monitoring (TDM) of vancomycin helps optimize treatment outcomes and reduce nephrotoxicity. Objectives: To describe the usage and TDM of vancomycin, treatment effectiveness, and nephrotoxic events. Materials and methods: A cross-sectional descriptive study was conducted on medical records of inpatients aged ≥18 years, receiving intermittent infusion of vancomycin for ≥ 3 days and having ≥ 1 TDM measurement (November 1^st 2023 - August 31^st 2024), at the study hospital. Data collected included patients’ characteristics, treatment and TDM details. Results: There were 66 patients included (mean age: 65,0 ± 18,5 years; male: 63,6%). MRSA was identified in 9 out of 63 cases (14,3%). Most patients received vancomycin as empiric therapy (69,7%). Loading dose was indicated in 21,2% of cases. Most patients had 1 - 2 TDM measurements during the course of vancomycin therapy (71,2%). The proportion of patients achieving target C_trough and treatment effectiveness were 65,2% and 63,6%, respectively. Nephrotoxicity occurred in 3/66 patients. Conclusions: The majority of patients were indicated vancomycin as empiric therapy and underwent 1 - 2 TDM measurements during treatment. The proportions of patients achieving target C_trough and treatment effectiveness were suboptimal.